Shares of Viyash Scientific Ltd. experienced a significant rally in Wednesday's trading session, climbing as much as 17.51% to reach a day's high of Rs 269 per share. The surge was propelled by the release of the company's strong financial results for the quarter ended March 31, 2026. At the close of trading, the pharmaceutical stock was up 12.41% at Rs 257.30 per share, contributing to an overall gain of nearly 24% over the past month.
Robust Financial Performance in Q4 FY26
According to regulatory filings submitted post-market hours on Tuesday, Viyash Scientific demonstrated impressive growth across all key performance indicators for the fourth quarter of the fiscal year 2026. Consolidated revenue from operations increased by 19.1% year-on-year, reaching Rs 919.96 crore, up from Rs 772.31 crore in the corresponding quarter of the previous year.
The company's bottom line saw a dramatic turnaround. Net profit attributable to shareholders stood at a solid Rs 52.11 crore. Overall profit after tax (PAT) skyrocketed to Rs 66.38 crore, a stark contrast to a loss of Rs 32.18 crore reported in the same quarter of the prior fiscal year.
Key Operational and Debt Improvements
- EBITDA Growth: Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose by 63.9% year-on-year to Rs 200.1 crore.
- Margin Expansion: Consequently, EBITDA margins expanded by 590 basis points, achieving a healthy 21.7%.
- Deleveraged Balance Sheet: The company's net debt to EBITDA ratio significantly improved, dropping to a comfortable 0.2x in Q4 FY26 from 1.0x in Q4 FY25.
Hari Babu Bodepudi, Managing Director and Group CEO of Viyash Scientific, commented on the results in the exchange filing. He noted, "Fiscal Year 2026 has been a transformative year for Viyash Scientific, marked by the successful integration of our facilities, operations, and corporate functions into one unified platform."
Looking ahead, Bodepudi expressed optimism: "As we enter FY27, we are excited about our product pipeline and growth roadmap. With a significantly deleveraged balance sheet, we are also actively evaluating selective inorganic opportunities to further strengthen our platform and create long-term value."